Atogepant for preventing episodic migraine in children
Treatments studied
Part of Brain & nervous system, Pain clinical trials.
This study tests whether an oral medicine called atogepant can reduce migraine activity in children ages 6–17 and checks its side effects. It’s meant for kids with episodic migraine (not the more constant types) who may benefit from preventive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 6 and 17 years old (and for the dosing “PK” part, specifically 6–11).
- Weigh at least 20 kg (44 lbs) and less than 135 kg (298 lbs).
- Have episodic migraine (with or without aura) for at least the past 6 months.
- During a 28-day period before the study, have 4 to 14 migraine days and fewer than 15 total headache days.
- Not have certain rare migraine types (migraine with brainstem aura, hemiplegic migraine, or retinal migraine).
- Not have chronic migraine or other non-migraine headache diagnoses like cluster headache, new daily persistent headache, or painful cranial nerve pain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a daily pill called atogepant to see how it affects the brain and body in people with episodic migraine. It may help if you have 8 to 14 migraine days a month and haven't tried CGRP treatments before.
This study tests a once-daily pill, atogepant, to see if it safely prevents chronic or episodic migraines in Korean adults. It's meant for people whose doctor has already prescribed the pill for migraine prevention.
This Phase 3 study tests eptinezumab to reduce migraine attacks in children who have episodic migraine (not daily chronic migraine). It may help by lowering the number of headache days and migraine days over time. You must complete a headache diary during screening to be considered.
This trial studies the long-term safety (side effects over time) of atogepant tablets in children and teens with migraine. It may help families understand whether the medicine is safe for longer use in ages 6 to 17.
This trial tests an oral medication called atogepant to see if it can prevent migraines in teens aged 12–17. It aims to reduce how often migraines happen and track any side effects.
This trial studies a medicine for stopping a migraine attack in children and teens. It may help families understand which treatment works best during acute (during-attack) migraine pain.
Hear when a new Episodic Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.